Bioline Rx Ltd ADR (BLRX) Unusual Options Activity Today

Checking BLRX unusual options activity helps you spot when traders are making outsized bets on Bioline Rx Ltd ADR before the broader market catches on. Bioline Rx Ltd ADR's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor BLRX unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching BLRX unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking BLRX unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and BLRX unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.

It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Catalysts rarely arrive without a footprint, and BLRX unusual options activity is often where that footprint shows up first. Our scanner tracks Bioline Rx Ltd ADR's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at BLRX unusual options volume on the call side or chasing put sweeps, Bioline Rx Ltd ADR's unusual options flow today is one click away, so put it on your radar before the headlines hit.